Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |
mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |